Elhmidi Y, Bleiziffer S, Piazza N, Voss B, Krane M, Deutsch M-A, Lange R
German Heart Centre Munich, Lazarettestrasse 36, 80636, Munich, Germany.
Curr Cardiol Rev. 2013 Nov;9(4):295-8. doi: 10.2174/1573403x09666131202124227.
Transcatheter aortic valve implantation (TAVI) is evolving rapidly as a therapeutic option in patients deemed to be at high risk for surgical aortic valve replacement. Early outcome and survival of controlled feasibility trials and single- center experience with TAVI have been previously reported. Valve performance and hemodynamics seem to improve significantly after TAVI. Long-term outcome up to 3 years have been demonstrated in recent studies. Admittedly, the results are encouraging with a survival rate at 2 and 3 years ranging from 62 to 74% and from 56 to 61% respectively. The improvement in hemodynamical and clinical status sustained beyond the 3 years follows up. However, paravalvular leakage after TAVI remains an important issue in this rapidely evolving field.
经导管主动脉瓣植入术(TAVI)作为一种治疗选择,在被认为进行外科主动脉瓣置换术风险较高的患者中正在迅速发展。此前已有关于TAVI对照可行性试验和单中心经验的早期结果及生存率的报道。TAVI术后瓣膜性能和血流动力学似乎有显著改善。近期研究显示了长达3年的长期结果。诚然,结果令人鼓舞,2年和3年生存率分别在62%至74%和56%至61%之间。血流动力学和临床状况的改善在3年随访期后仍持续存在。然而,在这个快速发展的领域,TAVI术后瓣周漏仍然是一个重要问题。